Praxis: Priced For Perfection Heading Into 2026
Source: SeekingAlpha
2025-12-31 08:15:40 ET
Introduction
Stock of Praxis Precision Medicines ( PRAX ) has continued north following Phase 3 data for its essential tremor, or ET, drug candidate, ulixacaltamide....
Read the full article on Seeking Alpha
For further details see:
Praxis: Priced For Perfection Heading Into 2026
Praxis Precision Medicines Inc.
NASDAQ: PRAX
PRAX Trading
-4.59% G/L:
$304.60 Last:
104,449 Volume:
$306.48 Open:
PRAX Latest News
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 04, 2026 04:01:00 pm
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2026 01:49:01 pm
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
February 22, 2026 02:36:11 pm
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
PRAX Stock Data
$8,057,264,446
20,105,683
0.7%
83
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
